AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05792644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib for rearrangement-negative, high phosphorylated ALK patients
Description: Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
Study NCT00934947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40 mg
Study NCT00934947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill
Study NCT00934947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Description: 120 mg twice per day
Study NCT05985213 — intervention group
Intervention type: OTHER
Intervention: data collection and follow-up
Description: Main measures and data collection methods:~1. Recording of baseline demographic and clinical information of the participants.~2. Multimodal magnetic resonance imaging~3. blood pressure variability.~4. neuropsychological testing~5. Blood samples collection
Study NCT01224821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab
Description: Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
Study NCT02710435 — intervention group
Intervention type: DEVICE
Intervention: Reducer System
Description: An aid in the management of chronic refractory angina pectoris
Study NCT04133896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6, Clusterin, Irisin Level
Description: Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
Study NCT01262170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CigRx Lozenge
Description: lozenge made of dietary supplements
Study NCT01262170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Lozenge
Description: lozenge made of compressed cured tobacco extract
Study NCT00819377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: inhaled milrinone 5 mg (as for the injectable solution)
Study NCT00819377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 5 ml normal saline by inhalation over 15 min
Study NCT00534378 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Midazolam
Description: The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
Study NCT00795834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High polyphenol beverage
Description: Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)
Study NCT00795834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)
Study NCT01170598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
Study NCT01768104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESTD
Description: 1. A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~2. Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~3. Dissection was done along the margin of the tumor.~4. After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~5. Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors... Endoscopy 2012; 44: 231-235)
Study NCT01768104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS
Description: 1. General anesthesia with double lumen intubation.~2. Three to four cameras or working ports are placed over the chest wall.~3. After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~4. The mass is exposed after the overlying muscle is split longitudinally.~5. The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~6. The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)
Study NCT03761381 — intervention group
Intervention type: DEVICE
Intervention: Noninvasive Retinal Amyloid Imaging (NRAI)
Description: The Spectralis will be used for NRAI. This system uses a special light source and optical filters to detect fluorescence of amyloid proteins in the eye.
Study NCT03315208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Description: The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based psychological intervention designed to be applied across anxiety, depressive, and other disorders in which emotion dysregulation is central. The UP targets shared temperamental vulnerabilities to emotional disorders through emotion-focused CBT strategies.
Study NCT03315208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
Study NCT03315208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
Study NCT00405587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX4032
Description: Oral capsules administered BID
Study NCT02829463 — intervention group
Intervention type: RADIATION
Intervention: Magnetic resonance imaging
Description: 3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
Study NCT01280214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 day 1
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclofosfamide
Description: 1200 mg/m2 day 1
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicina
Description: 70 mg/m2 day 1
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristina
Description: 1,4 mg/m2 (max 2 mg) day 1
Study NCT00337610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
Description: Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
Study NCT00337610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
Description: Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
Study NCT01861041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heavy Bupivacaine
Description: 7,5 mg intrathecal hyperbaric bupivacain,
Study NCT01861041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isobaric Bupivacaine
Description: 7.5 mg intratecal isobaric bupivacain
Study NCT03528304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Contingency management (CM) is a behavioral intervention that uses gift cards, prizes, or access to privileges to reinforce specific healthy behaviors and lifestyle changes. CM has been used successfully for a range of addictive behaviors, including cigarette smoking and heroin, cocaine, methamphetamine, and other illicit substance use, as well as for reducing psychiatric problems and HIV risk. CM has great potential for treating smoking and overweight/obesity, as it reinforces both short- and long-term behaviors. This is important because both smoking cessation and weight loss are highly prone to short-term relapse,
Study NCT01371799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug
Description: 4mg and 8mg Study drug
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg day g 1-5
Study NCT03817541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edmon (reg), BBraun
Description: exhaled propofol will be compared With plasma propofol values
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg day +1
Study NCT03086044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir
Description: 2 weeks of treatment beginning on the day of transplant
Study NCT03086044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
Study NCT03701373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 maintenance
Description: S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
Study NCT03701373 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Observation without anti-tumor treatment
Study NCT03803176 — intervention group
Intervention type: PROCEDURE
Intervention: Open Flap Debridement
Description: Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 8 mg/m2/days 1-3
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C
Description: 2000 mg/m2/12h day 1 - 3
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenograstim
Description: 5 μg/Kg/days +2
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300 mg/m2 day -7
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C
Description: 200 mg/m2/12 days -6,-5,-4,-3
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: 100 mg/m2/12h days -6,-5,-4,-3
Study NCT00499018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: PBSC Reinfusion
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclofosfamide
Description: 750 mg/m2 day 1
Study NCT02251366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physician-guided diagnostic
Description: NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
Study NCT02652611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SI Screw Removal Surgery
Study NCT02652611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-screw removal treatment (non-operative management)
Study NCT00499018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicina
Description: 50 mg/m2 day 1
Study NCT01633567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Targeted Cessation Program
Description: The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
Study NCT01633567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Targeted Cessation Program
Description: Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
Study NCT04027842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prewarming
Description: In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
Study NCT03898856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer
Description: 125 mg tablets taken by mouth twice daily for 28 days
Study NCT03898856 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic tests for cause of chronic diarrhea
Description: Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
Study NCT00724789 — intervention group
Intervention type: DRUG
Intervention: ganirelix
Description: Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
Study NCT00724789 — intervention group
Intervention type: DRUG
Intervention: GnRH agonist
Description: Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
Study NCT03949205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Extension Isometric Training
Description: The leg extension isometric exercise will be performed tree times a week , in four 2 min bouts of isometric contraction, at a intensity of 30% of maximal voluntary contraction and an interval of two minutes between bouts.
Study NCT04974112 — intervention group
Intervention type: OTHER
Intervention: Apply SGA and NRS2002
Description: Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information
Study NCT02734979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biobridge and lymph node transfer
Description: Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
Study NCT02826031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Injection
Study NCT02826031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DICL-SR
Study NCT02826031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DICL-SR
Study NCT03964155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sample
Description: After an exposure duration of at least 12 hours, a sample of directly-aspirated, undiluted pulmonary edema fluid will be collected concurrently with AnaConDa-S® filter collection.
Study NCT00746642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mellitor device for glucose measurement
Description: Glucose measurement using Mellitor device
Study NCT00746642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mellitor device for glucose measurement
Description: Glucose measurement using Mellitor device
Study NCT02089633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PACOX
Description: Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
Study NCT03066674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie group
Description: Mobilization for lumbar spine,TENS,Exercises,Postural education ,Home exercises program.
Study NCT03066674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: TENS,Exercises,Postural education ,Home exercises program.
Study NCT00740142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ornithine-L-aspartate and lactulose
Description: L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
Study NCT00740142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo and lactulose
Description: placebo 3 times a day for 7 days
Study NCT03128346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Transversus Plane Block
Description: The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.
Study NCT03128346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: IV, Hydromorphone
Study NCT03128346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone Hydrochloride
Description: IV, Hydromorphone
Study NCT03128346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral Aspirin
Study NCT03128346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Oral Aspirin
Study NCT03128346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Oral acetaminophen
Study NCT03128346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Oral acetaminophen
Study NCT03128346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: IV, fentanyl
Study NCT03046069 — intervention group
Intervention type: OTHER
Intervention: Telephone interviews
Description: Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
Study NCT03046069 — intervention group
Intervention type: OTHER
Intervention: In-person focus groups
Description: Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
Study NCT03046069 — intervention group
Intervention type: OTHER
Intervention: DCE surveys- cognitive interviews
Description: Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
Study NCT03046069 — intervention group
Intervention type: OTHER
Intervention: Modified DCE
Description: The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.